| P2093 | author name string | Maria J Cuadrado | |
| P2860 | cites work | Thrombosis, abortion, cerebral disease, and the lupus anticoagulant | Q24675412 |
| | Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment | Q28181800 |
| | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke | Q28192128 |
| | Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis | Q28192594 |
| | Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2. | Q31805095 |
| | Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients | Q74284472 |
| | Pregnancy complicated by the antiphospholipid syndrome: outcomes with intravenous immunoglobulin therapy | Q74601243 |
| | Guidelines on oral anticoagulation: third edition | Q74605668 |
| | Antithrombotic and thrombolytic therapy for ischemic stroke | Q77579080 |
| | The antiphospholipid syndrome | Q77739053 |
| | The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers | Q77871802 |
| | Low molecular weight heparins and heparin-induced thrombocytopenia | Q33331851 |
| | Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. | Q33342481 |
| | Antiphospholipid Thrombosis: Clinical Course after the First Thrombotic Event in 70 Patients | Q33369688 |
| | Clinical consequences of antiphospholipid antibodies: an historic cohort study | Q33492364 |
| | Thrombocytopenia in the antiphospholipid syndrome | Q33495555 |
| | A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis | Q33500954 |
| | Cerebrovascular ischemic events with high positive anticardiolipin antibodies | Q33504162 |
| | Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment | Q33565796 |
| | Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis | Q33744558 |
| | Antiplatelet therapy: new foundations for optimal treatment decisions. | Q33758225 |
| | Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature | Q33835528 |
| | Monitoring warfarin therapy in patients with lupus anticoagulants | Q34434408 |
| | The role of tissue factor in the antiphospholipid syndrome | Q34441079 |
| | Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness | Q37329482 |
| | Antiphospholipid antibody associated thrombosis: a consensus for treatment? | Q41442948 |
| | Chorea and antiphospholipid antibodies: treatment with methotrexate | Q43517040 |
| | Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype | Q43837381 |
| | Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins | Q45881942 |
| | A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis | Q47334930 |
| | Syndromes of thrombosis and hypercoagulability. Congenital and acquired causes of thrombosis | Q47911410 |
| | Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups | Q48090061 |
| | Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 |
| | A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism | Q49171054 |
| | Platelet-active drugs: the relationships among dose, effectiveness, and side effects | Q49171604 |
| | IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. | Q50933721 |
| | A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. | Q52078442 |
| | Point-of-care prothrombin time measurement for professional and patient self-testing use. A multicenter clinical experience. Oral Anticoagulation Monitoring Study Group. | Q53328287 |
| | Antiphospholipid Antibody Syndrome. | Q53330685 |
| | Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. | Q53337197 |
| | Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. | Q53354829 |
| | Antiphospholipid antibodies and venous thromboembolism | Q54157484 |
| | Warfarin and azathioprine: a drug interaction does exist. | Q54231629 |
| | Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial | Q57943255 |
| | Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry | Q71112355 |
| | Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men | Q72369034 |
| | Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin | Q72381346 |
| | The management of thrombosis in the antiphospholipid-antibody syndrome | Q72619159 |
| | Anticardiolipin antibodies and recurrent thromboembolism | Q73069585 |
| | Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study | Q73149725 |
| | Migraine in Hughes syndrome--heparin as a therapeutic trial? | Q73447481 |
| | Tissue factor pathway inhibitor: potential therapeutic applications | Q73447508 |
| | Antioxidant susceptibility of pathogenic pathways in subjects with antiphospholipid antibodies: a pilot study | Q73491960 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 392-8 | |
| P577 | publication date | 2002-10-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome) | |
| P478 | volume | 4 | |